Clinical Trials
16 trialsNCT04694495 2025-06-27
HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
Zhujiang Hospital
Completed
NCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT02873741 2019-11-06
ANCAR-WIHS
Emory University
Completed
NCT02572401 2019-10-15
STAND
University of Pennsylvania
Phase NA Completed
NCT02157168 2019-04-05
Connecting Healthy Women: Examining the Effect of an Intervention From the Effect of Being Reachable
University of Arizona
Phase NA Completed
NCT02724254 2018-07-20
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Vaxart
Phase 2 Completed
NCT02535104 2018-06-06
Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)
Tamir Biotechnology, Inc.
Phase 1/2 Completed
NCT01490359 2017-12-19
Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
University of Pennsylvania
Phase NA Completed
NCT00849823 2017-07-14
HIV Prevention Program for African American Teen Males
University of Kentucky
Phase NA Completed
NCT02401867 2017-06-28
Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients
Fenway Community Health
Completed
NCT01637324 2017-05-09
Multidisciplinary Services to Enhance HIV Testing and Linkage to Care Among MSM
Thai Red Cross AIDS Research Centre
Completed
NCT01043081 2016-05-11
WSW
University of Mississippi Medical Center
Completed
NCT01598779 2015-12-21
Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
University of Buenos Aires
Completed
NCT01117389 2015-08-27
Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer
St. Jude Children's Research Hospital
Completed
NCT00314028 2013-12-16
Effectiveness of HIV Risk Reduction Program Among African American Men
University of Kentucky
Phase 3 Completed